Inventiva (NASDAQ:IVA) Stock Breaks Above 50 Day Moving Average – Should You Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price crossed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $3.80 and traded as high as $3.99. Inventiva shares last traded at $3.83, with a volume of 3,248,993 shares.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Truist Financial raised their target price on Inventiva from $13.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. Weiss Ratings raised shares of Inventiva from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 23rd. Guggenheim raised their price objective on shares of Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Piper Sandler reiterated an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Finally, Cantor Fitzgerald initiated coverage on Inventiva in a report on Friday, July 17th. They set an “overweight” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Inventiva presently has a consensus rating of “Buy” and a consensus target price of $15.86.

Inventiva Stock Up 4.9%

The company has a 50-day simple moving average of $3.80 and a two-hundred day simple moving average of $4.88.

Inventiva (NASDAQ:IVA) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter. The company had revenue of $0.75 million for the quarter. Equities analysts anticipate that Inventiva S.A. Sponsored ADR will post -0.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new stake in shares of Inventiva during the 1st quarter worth about $1,111,000. Engineers Gate Manager LP lifted its position in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after purchasing an additional 43,280 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Inventiva by 78.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,600 shares of the company’s stock valued at $142,000 after purchasing an additional 17,000 shares in the last quarter. Platt Investment Counsel LLC acquired a new position in shares of Inventiva during the 3rd quarter valued at $45,000. Finally, Commonwealth Equity Services LLC raised its stake in shares of Inventiva by 7.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 89,853 shares of the company’s stock worth $332,000 after buying an additional 5,857 shares in the last quarter. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

Inventiva’s lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial.